India Drug Leaders Eye First-To-File In U.S. As Drugs Go Off-Patent
This article was originally published in PharmAsia News
Executive Summary
India's major drug makers such as Dr. Reddy's Laboratories, Glenmark, Lupin and Sun Pharmaceutical Industries can be expected to take advantage of $50 billion worth of U.S. drug patents going off-patent over the next five years.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.